Director Baynes Roy D. of Travere Therapeutics, Inc. (NASDAQ: TVTX) executed a pair of stock transactions on April 6, 2026, selling 10,000 shares of common stock at $33.00 per share for proceeds totaling $330,000 and simultaneously exercising stock options to obtain 10,000 additional shares at an exercise price of $26.52, valued at $265,200.
The sale price of $33.00 per share was slightly above the company’s then-current trading price of $31.67 and above the InvestingPro Fair Value estimate of $32.11, indicating the trade occurred near what InvestingPro characterizes as reasonable valuation. Following the sale and option exercise, Baynes Roy D. holds 37,500 shares of Travere Therapeutics directly.
InvestingPro data cited alongside the transaction notes that Travere’s stock has risen 109% over the prior 12 months. The combination of an insider sale and an option exercise resulted in both liquidity for the director and an increased direct ownership position after the exercised options were converted into shares.
Separately, Travere disclosed a regulatory development for its supplemental New Drug Application (sNDA) for Filspari, a therapy intended to treat focal segmental glomerulosclerosis (FSGS). The U.S. Food and Drug Administration extended the review period by three months after the company provided additional information at the agency’s request. As a result, the Prescription Drug User Fee Act (PDUFA) target action date is now April 13, 2026. The FDA classified Travere’s responses as a Major Amendment to the filing, which triggered the extended review timeline.
The company submitted supplemental material to further characterize the clinical benefit of Filspari; those responses are now under FDA review. Stifel has reiterated a Hold rating on Travere’s shares and kept a $31.00 price target. The analyst note and the FDA’s Major Amendment designation together underscore a degree of regulatory uncertainty as the revised PDUFA date approaches.
The intertwined developments - insider activity and prolonged regulatory review - leave market participants with clear, stated facts but without definitive resolution until the FDA completes its review. Travere’s stock performance over the past year and the director’s post-transaction ownership position are measurable data points that investors can weigh alongside the pending regulatory outcome for Filspari.
Key details - all figures and dates reported by the company or InvestingPro - remain as disclosed: 10,000 shares sold at $33.00 for $330,000; 10,000 options exercised at $26.52 for $265,200; direct ownership of 37,500 shares following the transactions; 109% one-year return per InvestingPro; and an April 13, 2026 PDUFA date after a three-month FDA extension.